Melanoma vaccine - Amgen
Alternative Names: ImmunoVEX tri-melanLatest Information Update: 02 Oct 2021
At a glance
- Originator BioVex
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 29 May 2007 No development reported - Phase-I/II for Malignant melanoma in Canada (unspecified route)
- 29 May 2007 No development reported - Phase-I/II for Malignant melanoma in United Kingdom (unspecified route)
- 29 Apr 2005 Phase-I/II clinical trials in Malignant melanoma in Canada (unspecified route)